JP4551502B2 - 病原体不活化のための脆い化合物 - Google Patents

病原体不活化のための脆い化合物 Download PDF

Info

Publication number
JP4551502B2
JP4551502B2 JP53119998A JP53119998A JP4551502B2 JP 4551502 B2 JP4551502 B2 JP 4551502B2 JP 53119998 A JP53119998 A JP 53119998A JP 53119998 A JP53119998 A JP 53119998A JP 4551502 B2 JP4551502 B2 JP 4551502B2
Authority
JP
Japan
Prior art keywords
alkyl
heteroalkyl
heteroaryl
aryl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP53119998A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001508449A (ja
JP2001508449A5 (enExample
Inventor
クック，デイビッド
メリット，ジョン
ネリオ，アイリーン
ラポポート，ヘンリー
スタシノポウロス，アドニス
ウォロウィッツ，スーザン
マテジョビック，ジャン
Original Assignee
セラス コーポレーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セラス コーポレーション filed Critical セラス コーポレーション
Publication of JP2001508449A publication Critical patent/JP2001508449A/ja
Publication of JP2001508449A5 publication Critical patent/JP2001508449A5/ja
Application granted granted Critical
Publication of JP4551502B2 publication Critical patent/JP4551502B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Disinfection or sterilisation of materials or objects, in general; Accessories therefor
    • A61L2/16—Disinfection or sterilisation of materials or objects, in general; Accessories therefor using chemical substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/02—Blood transfusion apparatus
    • A61M1/0209—Multiple bag systems for separating or storing blood components
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/28—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties
    • B01J20/28014—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties characterised by their form
    • B01J20/28033—Membrane, sheet, cloth, pad, lamellar or mat
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D219/00—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems
    • C07D219/04—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C07D219/08—Nitrogen atoms
    • C07D219/10—Nitrogen atoms attached in position 9
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/64—Acridine or hydrogenated acridine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2103/00—Materials or objects being the target of disinfection or sterilisation
    • A61L2103/05—Living organisms or biological materials
    • A61L2103/09—Blood or products thereof

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Apparatus For Disinfection Or Sterilisation (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Peptides Or Proteins (AREA)
JP53119998A 1997-01-06 1998-01-06 病原体不活化のための脆い化合物 Expired - Lifetime JP4551502B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US77988597A 1997-01-06 1997-01-06
US08/779,885 1997-01-06
US77983097A 1997-01-07 1997-01-07
US08/779,830 1997-01-07
US4369697P 1997-04-15 1997-04-15
US60/043,696 1997-04-15
PCT/US1998/000532 WO1998030545A1 (en) 1997-01-06 1998-01-06 Frangible compounds for pathogen inactivation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009286996A Division JP5244083B2 (ja) 1997-01-06 2009-12-17 病原体不活化のための脆い化合物

Publications (3)

Publication Number Publication Date
JP2001508449A JP2001508449A (ja) 2001-06-26
JP2001508449A5 JP2001508449A5 (enExample) 2005-09-08
JP4551502B2 true JP4551502B2 (ja) 2010-09-29

Family

ID=27366374

Family Applications (2)

Application Number Title Priority Date Filing Date
JP53119998A Expired - Lifetime JP4551502B2 (ja) 1997-01-06 1998-01-06 病原体不活化のための脆い化合物
JP2009286996A Expired - Lifetime JP5244083B2 (ja) 1997-01-06 2009-12-17 病原体不活化のための脆い化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2009286996A Expired - Lifetime JP5244083B2 (ja) 1997-01-06 2009-12-17 病原体不活化のための脆い化合物

Country Status (9)

Country Link
EP (1) EP1021414B1 (enExample)
JP (2) JP4551502B2 (enExample)
CN (2) CN101676268B (enExample)
AT (1) ATE243198T1 (enExample)
AU (1) AU744089C (enExample)
CA (1) CA2276532C (enExample)
DE (1) DE69815703T2 (enExample)
ES (1) ES2196530T3 (enExample)
WO (1) WO1998030545A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010095527A (ja) * 1997-01-06 2010-04-30 Cerus Corp 病原体不活化のための脆い化合物

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69826521T2 (de) * 1998-01-06 2005-09-29 Cerus Corp., Concord Verfahren zum quenchen von pathogen-inaktivatoren in biologischen materialien
US6281225B1 (en) 1998-06-11 2001-08-28 Cerus Corporation Inhibiting proliferation of arterial smooth muscle cells
US7049110B2 (en) 1998-07-21 2006-05-23 Gambro, Inc. Inactivation of West Nile virus and malaria using photosensitizers
US7498156B2 (en) 1998-07-21 2009-03-03 Caridianbct Biotechnologies, Llc Use of visible light at wavelengths of 500 to 550 nm to reduce the number of pathogens in blood and blood components
US6403359B1 (en) 1998-09-25 2002-06-11 V. I. TECHNOLOGIES, Inc. Solid phase quenching systems
US6150109A (en) 1999-01-25 2000-11-21 V. I. TECHNOLOGIES, Inc. Lipophilic quenching of viral inactivating agents
US7094378B1 (en) 2000-06-15 2006-08-22 Gambro, Inc. Method and apparatus for inactivation of biological contaminants using photosensitizers
US7220747B2 (en) 1999-07-20 2007-05-22 Gambro, Inc. Method for preventing damage to or rejuvenating a cellular blood component using mitochondrial enhancer
CN1436083A (zh) * 2000-05-31 2003-08-13 塞鲁斯公司 制备病原体灭活的低免疫原性红细胞溶液
US9044523B2 (en) 2000-06-15 2015-06-02 Terumo Bct, Inc. Reduction of contaminants in blood and blood products using photosensitizers and peak wavelengths of light
DE10051628B4 (de) * 2000-10-18 2007-06-06 Fresenius Hemocare Beteiligungs Gmbh Einzelsträngiges Oligonukleotid und dessen Verwendung
US20030113704A1 (en) * 2000-12-21 2003-06-19 Cerus Corporation Methods for inactivation of pathogens in biological materials
KR101173871B1 (ko) * 2003-02-06 2012-08-16 앤저 테라퓨틱스 인코퍼레이티드 변형된 독립생존 미생물, 백신 조성물 및 그것의 사용방법
US7695725B2 (en) 2003-02-06 2010-04-13 Aduro Biotech Modified free-living microbes, vaccine compositions and methods of use thereof
ATE552843T1 (de) 2003-02-06 2012-04-15 Aduro Biotech Listerien deren eindringen in nicht-phagozytische zellen abgeschwächt ist, impfstoffe, die diese listerien enthalten und deren verwendungen
US7842289B2 (en) 2003-12-24 2010-11-30 Aduro Biotech Recombinant nucleic acid molecules, expression cassettes, and bacteria, and methods of use thereof
JP5346468B2 (ja) 2004-10-29 2013-11-20 シーラス コーポレイション 赤血球不活性化プロセスのための改善されたクエンチング方法
KR101896430B1 (ko) 2008-04-09 2018-09-10 세루스 코포레이션 적혈구 병원체 불활성화를 위한 개선된 퀀칭 방법
US9353122B2 (en) 2013-02-15 2016-05-31 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US9353123B2 (en) 2013-02-20 2016-05-31 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
KR20160099084A (ko) 2013-11-01 2016-08-19 칼라 파마슈티컬스, 인크. 치료 화합물의 결정질 형태 및 그의 용도
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
CN104788373A (zh) * 2015-05-06 2015-07-22 武汉大学 化合物s-303盐酸盐的合成方法
CN122182613A (zh) 2015-06-26 2026-06-12 塞鲁斯公司 冷沉淀物组合物及其制备方法
CN104991033A (zh) * 2015-08-05 2015-10-21 上海海虹实业(集团)巢湖今辰药业有限公司 一种采用一测多评法测定川芎挥发油成分的方法
US10799533B2 (en) 2015-10-23 2020-10-13 Cerus Corporation Plasma compositions and methods of use thereof
WO2018048750A1 (en) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
EP3509421A4 (en) 2016-09-08 2020-05-20 Kala Pharmaceuticals, Inc. CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF
US10253036B2 (en) 2016-09-08 2019-04-09 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
AU2017382449B2 (en) * 2016-12-23 2024-10-24 Cerus Corporation Systems and methods for testing and screening using compound bound substrates
EP4606379A3 (en) 2017-03-03 2025-11-19 Cerus Corporation Kits and methods for preparing pathogen-inactivated platelet compositions
JP7311518B2 (ja) 2017-12-29 2023-07-19 シーラス コーポレイション 生物学的流体を処理するためのシステムおよび方法
WO2020263745A1 (en) 2019-06-22 2020-12-30 Cerus Corporation Systems and methods for implementing treatment of biological fluids
CN114173842B (zh) 2019-06-22 2026-07-14 塞鲁斯公司 生物流体处理系统
JP7645203B2 (ja) 2019-06-28 2025-03-13 シーラス コーポレイション 生物学的流体処理デバイスを実装するためのシステム及び方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6402494A (en) * 1993-03-11 1994-09-26 Steritech, Inc. Decontaminating clinical samples
US5691132A (en) * 1994-11-14 1997-11-25 Cerus Corporation Method for inactivating pathogens in red cell compositions using quinacrine mustard
DE4444045C2 (de) * 1994-12-10 1997-04-17 Behringwerke Ag Verfahren zur Inaktivierung von Viren mit Hilfe von Acridin oder Acridinderivaten
EP0773716A4 (en) * 1995-06-07 1999-08-04 Cerus Corp TREATMENT OF RED BLOOD CELL SOLUTIONS WITH ANTIVRAL ACTIVE SUBSTANCES
ATE243198T1 (de) * 1997-01-06 2003-07-15 Cerus Corp Verbindungen mit leicht spaltbaren bindungen zur inaktivierung von pathogenen

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010095527A (ja) * 1997-01-06 2010-04-30 Cerus Corp 病原体不活化のための脆い化合物

Also Published As

Publication number Publication date
HK1188441A1 (en) 2014-05-02
EP1021414A1 (en) 2000-07-26
ES2196530T3 (es) 2003-12-16
CA2276532A1 (en) 1998-07-16
JP2001508449A (ja) 2001-06-26
AU744089B2 (en) 2002-02-14
JP2010095527A (ja) 2010-04-30
CA2276532C (en) 2008-06-17
WO1998030545A1 (en) 1998-07-16
CN1248245B (zh) 2012-07-04
CN101676268B (zh) 2013-09-25
DE69815703T2 (de) 2004-06-03
AU744089C (en) 2003-07-31
HK1026702A1 (en) 2000-12-22
AU5821798A (en) 1998-08-03
CN101676268A (zh) 2010-03-24
ATE243198T1 (de) 2003-07-15
DE69815703D1 (de) 2003-07-24
EP1021414B1 (en) 2003-06-18
CN1248245A (zh) 2000-03-22
JP5244083B2 (ja) 2013-07-24

Similar Documents

Publication Publication Date Title
JP5244083B2 (ja) 病原体不活化のための脆い化合物
US6093725A (en) Frangible compounds for pathogen inactivation
US6514987B1 (en) Frangible compounds for pathogen inactivation
WO1998030545A9 (en) Frangible compounds for pathogen inactivation
JP4643004B2 (ja) 生体材料中の病原体不活性化剤をクエンチするための方法
JP3145124B2 (ja) 抗ウイルス剤による赤血球溶液の処理
EP1032265B1 (en) New psoralens for pathogen inactivation
US20030113704A1 (en) Methods for inactivation of pathogens in biological materials
JP2003534383A (ja) 免疫原性が減少した赤血球の病原体不活性化溶液の調製
JP2004518766A (ja) ハロゲン化ローダミン誘導体およびその適用
HK1026702B (en) Frangible compounds for pathogen inactivation
HK1188441B (en) Frangible compounds for pathogen inactivation
EP1364944A1 (en) Frangible Compounds for Pathogen Inactivation
SU1650014A3 (ru) Способ получени конденсированных производных пиримидина, их фармацевтически приемлемых кислых аддитивных солей или кислых аддитивных солей гидратов
JP2005524707A (ja) 核酸の修飾のための方法および組成物
AU4899100A (en) Method and devices for the removal of psoralens from blood products

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20041228

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20041228

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20081021

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20081226

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090209

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20090408

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090818

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091217

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20100224

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20100401

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20100706

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20100712

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130716

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term